https://pharminent.com/market-access/market-access-intelligence-weekly-digest-june-26-2026/ 2026-06-27T17:13:15Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • June 26, 2026 2026-06-27T17:13:13Z Blog https://pharminent.com/lilly-medicare-glp-1-bridge-launches-july-1-with-foundayo-and-zepbound/ 2026-06-26T19:53:45Z Pharminent en Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound 2026-06-26T19:53:45Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-june-26-2026/ 2026-06-26T19:38:32Z Pharminent en GLP-1 Competitive Market Digest • Weekly • June 26, 2026 2026-06-26T19:38:29Z Blog https://pharminent.com/moderna-maps-rd-horizons-as-2028-break-even-goal-looms/ 2026-06-26T20:20:06Z Pharminent en Moderna Maps R&D 'Horizons' as 2028 Break-Even Goal Looms 2026-06-26T16:53:32Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-26-2026/ 2026-06-26T16:49:15Z Pharminent en Strategic News Watch • June 26, 2026 2026-06-26T16:49:12Z Blog https://pharminent.com/replimune-gets-early-august-decision-date-for-twice-rejected-melanoma-drug/ 2026-06-26T15:33:32Z Pharminent en Replimune gets early August decision date for twice-rejected melanoma drug 2026-06-26T13:57:00Z Blog https://pharminent.com/moderna-looks-out-to-rd-horizons-as-2028-break-even-goal-looms/ 2026-06-26T15:33:46Z Pharminent en Moderna looks out to R&D 'horizons' as 2028 break-even goal looms 2026-06-26T12:00:38Z Blog https://pharminent.com/immunai-and-boehringer-partner-to-identify-t-cell-targets/ 2026-06-26T15:34:24Z Pharminent en Immunai and Boehringer partner to identify T-cell targets 2026-06-26T10:41:21Z Blog https://pharminent.com/ionis-grants-recordati-rights-to-zilganersen-for-alexander-disease-2/ 2026-06-26T15:34:53Z Pharminent en Ionis grants Recordati rights to zilganersen for Alexander disease 2026-06-26T09:17:11Z Blog